Transforming Medical Technology with Groundbreaking Implants
SINGAPORE – Syntellix AG, a pioneering German leader in bioabsorbable metallic implants for orthopaedics and trauma surgery, has cemented its presence in Singapore as a second headquarters. Serving 70 countries globally, the firm operates a manufacturing facility in Tuas Biomedical Park, reinforcing Singapore’s position as a hub for medical innovation.
CEO Prof Utz Claassen emphasised Singapore’s unique strengths: “The Republic combines world-class hospitals, outstanding academic institutions, robust governance, and political stability. It’s also an excellent talent pool for highly skilled professionals.” Currently employing 90 staff globally, with 20% based in Singapore, Syntellix plans to significantly expand its workforce here, aiming for 775 employees by 2026.
A Catalyst for Advanced Healthcare
Syntellix’s MAGNEZIX® implants are at the forefront of medical technology. Made from a patented magnesium alloy, these bioabsorbable devices provide metallic stability while gradually transforming into bone tissue, eliminating the need for secondary surgeries. This innovation not only enhances patient outcomes but also reduces risks associated with traditional implants, such as infection and prolonged recovery times.
“MAGNEZIX® offers a remarkable combination of benefits: reduced pain, faster healing, fewer complications, and cost savings. Surgeons recognise it as the new ‘gold standard’,” Prof Claassen stated. Clinical studies in peer-reviewed journals consistently highlight its superiority over conventional titanium implants.
Singapore as a Launchpad for Global Growth
Initially established to market its products regionally, Syntellix’s Singapore subsidiary has surpassed expectations, achieving monthly growth rates exceeding 50% during the pandemic. This success led to the creation of a manufacturing site in Singapore, accelerating distribution across Asia. The company is now in the process of quadrupling production capacity and integrating additional processes, positioning Singapore as a cornerstone of its global value chain.
Prof Claassen attributes this rapid growth to Singapore’s unparalleled support for innovation. “With its Economic Development Board, Health Sciences Authority, and Singapore Exchange, the country offers a phenomenal ecosystem for growth and collaboration,” he remarked.
A Visionary Future in Healthcare
Syntellix envisions a transformative era for orthopaedic technology, with magnesium implants replacing traditional materials like titanium. This shift could save thousands of lives annually by reducing the risks associated with implant removal surgeries and hospital-acquired infections. “Our mission is to provide intelligent innovations for better lives,” Prof Claassen explained, adding that the company’s implants also offer anti-inflammatory benefits and improved biomechanical compatibility with human bone.
With approvals in 70 countries, including recognition by the US FDA as a “Breakthrough Device,” Syntellix continues to lead the way in orthopaedic advancements. From its Singapore hub, the company is poised to revolutionise patient care globally while solidifying its role as a technological trailblazer.
